Acta Neuropharmacologica››2011,Vol. 1››Issue (4): 48-54.
Previous ArticlesNext Articles
LIU Shao-qiang1,2,TIE Lu1,LI Xue-jun1
Online:
2011-08-26Published:
2012-11-241 Grant R Zimmermann, Joseph Lehar, Curtis T Keith. Multi-target therapeutics: when the whole is greater than the sum of the parts[J]. Drug Discov Today, 2007, 12(1-2):34-42. 2 Peter Csermely, Vilmos Agoston, Sandor Pongor. The efficiency of multi-target drugs: the network approach might help drug design[J]. Trends Pharmacol Sci, 2005, 26(4):178-182. 3 Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases[J]. Expert Rev Clin Pharmacol,2011, 4(3):293-298. 4 Bajda M, Guzior N, Ignasik M, et al. Multi-target-directed ligands in Alzheimer's disease treatment[J]. Curr Med Chem, 2011, 18(32):4949-4975. 5 Min-Hee Pang, Yuntae Kim, Kyung Woon Jung, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs[J]. Drug Discov Today, 2012,17(9-10):425-434. 6 Ohlson S. Designing transient binding drugs: a new concept for drug discovery[J]. Drug Discov Today, 2008, 13(9-10):433-439. 7 Richard Morphy, Corinne Kay, Zoran Rankovic. From magic bullets to designed multiple ligands[J]. Drug Discovery Today, 2004, 9(15):641-651. 8 Louis M Tsai, Di Yu. MicroRNAs in common diseases and potential therapeutic applications[J]. Clin Exp Pharmacol Physiol, 2010, 37(1):102-107. 9 Ranjan J Perera, Animesh Ray. MicroRNAs in the search for understanding human diseases[J]. Bio drugs, 2007, 21(2):97-104. 10 Boutla A, Delidakis C, Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identi?cation of putative target genes[J]. Nucleic Acids Res, 2003, 31(17):4973-4980. 11 Gayathri R Devi, Tomasz M Beer, Christopher L Corless, et al. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors[J]. Clin Cancer Res, 2005, 11(10):3930-3938. 12 Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides[J]. Gene Ther, 2011, 18(12):1111-1120. 13 Lu Y, Xiao J, Lin H, et al. Complex antisense inhibitors offer a superior approach for microRNA research and therapy[J]. Nucleic Acids Res, 2009, 37:e24-e33. 14 Thomas Thum, Paolo Galuppo, Christian Wolf, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure[J]. Circulation, 2007, 116(3):258-267. 15 Stefano Volinia, George A Calin, Liu Changgong, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci U S A, 2006, 103(7):2257-2261. 16 Meng Qingwen, Zhang Zaiping, Wang Wen, et al. Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs[J]. Virol J, 2011, 8(1):556. 17 Pranavan Thillaivinayagalingam, Julien Gommeaux, Michael McLoughlin, et al. Biopharmaceutical production: Applications of surface plasmon resonance biosensors[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878(2):149-153. 18 Visser NF, Heck AJ. Surface plasmon resonance mass spectrometry in proteomics[J]. Expert Rev Proteomics, 2008, 5(3):425-433. 19 Jacquemart R, Chavane N, Durocher Y, et al. At-line monitoring of bioreactor protein production by Surface Plasmon Resonance[J]. Biotechnol Bioeng, 2008, 100(1):184-188. 20 Bader B, Kuhn K, Owen DJ, et al. Bioorganic synthesis of lipid-modified proteins for the study of signal transduction[J]. Nature, 2000, 403(6766):223-226. 21 Anthony M Giannetti, Bruce D Koch, Michelle F Browner. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors[J]. J Med Chem, 2008, 51(3):574-580. 22 Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery[J]. Future Med Chem, 2011, 3(14):1809-1820. 23 Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(18):5321-5324. 24 Neumann T, Junker HD, Schmidt K, et al. SPR-based fragment screening: advantages and applications[J]. Curr Top Med Chem, 2007, 7(16):1630-1642. 25 Stephen S Antonysamy, Brandon Aubol, Jeff Blaney, et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(9):2990-2995. 26 Baty JW, Hampton MB, Winterbourn CC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis[J]. Proteomics, 2002, 2(9):1261-1266. 27 Wang Hong, Hanash S. Multi-dimensional liquid phase based separations in proteomics[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 787(1):11-18. 28 Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development[J]. Current Mol Med, 2005, 5(1):39-52. 29 Zhang Xiang, Fang Aiqin, Catherine P Riley, et al. Multi-dimensional liquid chromatography in proteomics-A review[J]. Anal Chim Acta, 2010, 664(2):101-113. 30 Scott W Simpkins, Jeremy W Bedard, Stephen R Groskreutz, et al. Targeted three-dimensional liquid chromatography: a versatile tool for quantitative trace analysis in complex matrices[J]. J Chromatogr A, 2010, 1217(49):7648-7660. 31 Gao M, Qi D, Zhang P, et al. Development of multidimensional liquid chromatography and application in proteomic analysis[J]. Expert Rev Proteomics, 2010, 7(5):665-678. 32 Baynham MT, Patel S, Moaddel R, et al. Multidimensional on-line screening for ligands to the alpha3beta4 neuronal nicotinic acetylcholine receptor using an immobilized nicotinic receptor liquid chromatographic stationary phase[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 772(1):155-161. 33 Dai Jie, Jin Wenhai, Sheng Quanhu, et al. Protein phosphorylation and expression profiling by Yin-Yang multidimensional liquid chromatography (Yin-Yang MDLC) mass spectrometry[J]. J Proteome Res, 2007, 6(1):250-262. 34 Hao P, Qian J, Dutta B, et al. Enhanced Separation and Characterization of Deamidated Peptides with RP-ERLIC-Based Multidimensional Chromatography Coupled with Tandem Mass Spectrometry[J]. J Proteome Res, 2012,11(3):1804-1811. 35 Martin Vollmer, Edgar Nägele, Patric Hörth. Differential Proteome Analysis: Two-Dimensional Nano-LC/MS of E.Coli Proteome Grown on Different Carbon Sources[J]. J Biomol Tech, 2003, 14(2):128-135. 36 Jae Hong Kim, Ji Hyun Yeom, Jeong Jae Ko, et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles[J]. J Biotechnol, 2011, 155(3):287-292. 37 Yoshida M, Loo JA, Lepley RA. Proteomics as a tool in the pharmaceutical drug design process[J]. Curr Pharm Des, 2001, 7(4):291-310. |
No related articles found! |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||